AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AIMOVIG® (erenumab-aooe)	Neuroscience	Pediatric Migraine	Monoclonal Antibody	3
	DESCRIPTION Aimovig is a monoclonal antibody that inhibits the calcitonin gene-related peptide receptor (CGRP-R). It is being investigated for prevention of chronic and episodic migraine in pediatric patients. **ADDITIONAL INFORMATION** Aimovig is developed in partnership with Novartis.			
AMJEVITA® (adalimumab-atto)	Inflammation	Interchangeability	Monoclonal Antibody	3
	DESCRIPTION AMJEVITA (adalimumab-atto) is a biosimilar to HUMIRA® (adalimumab), which is a monoclonal antibody that inhibits binding of TNF-alpha to cell surface TNF receptor / TNF-alpha. **ADDITIONAL INFORMATION** HUMIRA is a registered trademark of AbbVie Biotechnology Ltd. AMJEVITA is a trademark of Amgen Inc.			
BEMARITUZUMAB	Hematology/Oncology	Gastric and Gastroesophageal Junction (GEJ) Cancers	Monoclonal Antibody	3
	DESCRIPTION Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric and Gastroesophageal Junction (GEJ) Cancers. **ADDITIONAL INFORMATION** In April 2021, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation for bemarituzumab. **ADDITIONAL CLINICAL STUDIES** Bemarituzumab is also in Phase 1 and Phase 2 development for the treatment of advanced Gastric and Gastroesophageal cancers in combination with other therapies.			
	Hematology/Oncology	Other Tumors	Monoclonal Antibody	2
	DESCRIPTION Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced solid tumors other than advanced squamous non-small cell lung cancer.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
BLINCYTO® (blinatumomab)	Hematology/Oncology	Acute Lymphoblastic Leukemia	BiTE® Molecule	3
	DESCRIPTION BLINCYTO is an anti-CD19 x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated for the treatment of newly diagnosed adults and pediatric patients with B-Cell precursor Acute Lymphoblastic Leukemia (ALL). **ADDITIONAL INFORMATION** In October 2023, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation to BLINCYTO. **ADDITIONAL CLINICAL STUDIES** BLINCYTO is also in Phase 1 development being investigated for subcutaneous administration for the treatment of adults with relapsed/refractory Acute Lymphoblastic Leukemia (ALL).			
DAZODALIBEP	Rare Disease	Sjögren's Disease	Fusion Protein	3
	DESCRIPTION Dazodalibep is a fusion protein binding CD40L on T cells, blocking their interaction with CD40-expressing B cells. It is being investigated for the treatment of Sjögren's disease.			
EVENITY® (romosozumab-aqqg)	Bone	Male Osteoporosis	Monoclonal Antibody	3
	DESCRIPTION EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of male osteoporosis. **ADDITIONAL INFORMATION** EVENITY is being developed in collaboration with UCB.			
	Bone	Pediatric Osteogenesis Imperfecta	Monoclonal Antibody	3
	DESCRIPTION EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients. **ADDITIONAL INFORMATION** EVENITY is being developed in collaboration with UCB.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
KYPROLIS® (carfilzomib)	Hematology/Oncology	Multiple Myeloma	Small Molecule	3
	DESCRIPTION KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for weekly dosing in combination with lenalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma.			
	Hematology/Oncology	Pediatric Acute Lymphoblastic Leukemia	Small Molecule	2
	DESCRIPTION KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients.			
LUMAKRAS® (sotorasib)	Hematology/Oncology	Advanced Colorectal Cancer	Small Molecule	3
	DESCRIPTION LUMAKRAS is a $KRAS^{G12C}$ small molecule inhibitor under investigation for the treatment of advanced colorectal cancer. **ADDITIONAL INFORMATION** In August 2023, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation to LUMAKRAS. **ADDITIONAL CLINICAL STUDIES** LUMAKRAS is being investigated in previously treated KRAS G12C-mutated CRC in combination with other therapies.			
	Hematology/Oncology	Non-Small Cell Lung Cancer	Small Molecule	3
	DESCRIPTION LUMAKRAS is a $KRAS^{G12C}$ small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer. **ADDITIONAL INFORMATION** LUMAKRAS received accelerated approval by the FDA in May 2021 for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, following at least one prior systemic therapy. Marketing authorization has subsequently been granted in the European Union as well as in additional countries, including some under FDA's Project Orbis initiative, such as Canada and U.K. Additional marketing applications are also under review. **ADDITIONAL CLINICAL STUDIES** LUMAKRAS is also in Phase 1 and Phase 2 development for the treatment of NSCLC in combination with other therapies.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
LUMAKRAS® (sotorasib)	Hematology/Oncology	Other Tumors	Small Molecule	2
	DESCRIPTION LUMAKRAS is a $KRAS^{G12C}$ small molecule inhibitor under investigation for the treatment of advanced solid tumors other than non-small cell lung cancer or advanced colorectal cancer. **ADDITIONAL CLINICAL STUDIES** LUMAKRAS is being investigated in previously treated KRAS G12C-mutated solid tumors in combination with other therapies.			
NPLATE® (romiplostim)	Hematology/Oncology	Chemotherapy-Induced Thrombocytopenia	Peptibody	3
	DESCRIPTION Nplate is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of chemotherapy-induced thrombocytopenia (CIT).			
OLPASIRAN (formerly AMG 890)	Cardiometabolic	Cardiovascular Disease	siRNA	3
	DESCRIPTION Olpasiran (formerly AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated for the treatment of atherosclerotic cardiovascular disease.			
OTEZLA® (apremilast)	Inflammation	Pediatric Plaque Psoriasis	Small Molecule	3
	DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe plaque psoriasis in pediatric patients.			
	Inflammation	Juvenile Psoriatic Arthritis	Small Molecule	3
	DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of juvenile psoriatic arthritis in pediatric patients.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
OTEZLA® (apremilast)	Inflammation	Pediatric Behcet's Disease	Small Molecule	3
	DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of Behcet's disease in pediatric patients.			
	Inflammation	Palmoplantar Pustulosis	Small Molecule	3
	DESCRIPTION Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of palmoplantar pustulosis.			
PARSABIV® (etelcalcetide)	Nephrology	Pediatric Secondary Hyperparathyroidism	Peptide	3
	DESCRIPTION Parsabiv is a calcium-sensing receptor agonist. It is being investigated for the treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease (CKD) receiving hemodialysis.			
PROLIA® (denosumab)	Bone	Pediatric Glucocorticoid-Induced Osteoporosis	Monoclonal Antibody	3
	DESCRIPTION Prolia is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of glucocorticoid-induced osteoporosis (GIOP) in pediatric patients.			
REPATHA® (evolocumab)	Cardiometabolic	Hypercholesterolemia	Monoclonal Antibody	3
	DESCRIPTION Repatha is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated in patients at high cardiovascular risk without a prior myocardial infarction or stroke.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
ROCATINLIMAB (formerly AMG 451 / KHK4083)	Inflammation	Atopic Dermatitis	Monoclonal Antibody	3
	DESCRIPTION Rocatinlimab (formerly AMG 451 / KHK4083) is an anti-OX40 monoclonal antibody that inhibits and removes OX40 expressing pathogenic effector and memory T cells. It is being investigated for the treatment of moderate-to-severe atopic dermatitis. **ADDITIONAL INFORMATION** Rocatinlimab is being developed in collaboration with Kyowa Kirin Co., Ltd.			
	Inflammation	Asthma	Monoclonal Antibody	2
	DESCRIPTION Rocatinlimab (formerly AMG 451 / KHK4083) is an anti-OX40 monoclonal antibody that inhibits and removes OX40 expressing pathogenic effector and memory T cells. It is being investigated for the treatment of moderate-to-severe asthma. **ADDITIONAL INFORMATION** Rocatinlimab is being developed in collaboration with Kyowa Kirin Co., Ltd.			
TARLATAMAB (formerly AMG 757)	Hematology/Oncology	Small Cell Lung Cancer	BiTE® Molecule	3
	DESCRIPTION Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of small cell lung cancer. **ADDITIONAL INFORMATION** In October 2023, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation for tarlatamab. **ADDITIONAL CLINICAL STUDIES** Tarlatamab is also in Phase 1 in combination with other therapies.			
	Hematology/Oncology	Neuroendocrine Prostate Cancer	BiTE® Molecule	1
	DESCRIPTION Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of neuroendocrine prostate cancer.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
TAVNEOS® (avacopan)	Rare Disease	Pediatric Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis	Small Molecule	3
	DESCRIPTION TAVNEOS is a complement 5a receptor (C5aR) antagonist that inhibits the effects of C5a. It is being investigated for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)) in pediatric patients.			
TEPEZZA® (teprotumumab-trbw)	Rare Disease	Thyroid Eye Disease	Monoclonal Antibody	3
	DESCRIPTION TEPEZZA is a monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R). It is being investigated for subcutaneous administration for the treatment of moderate-to-severe active thyroid eye disease.			
TEZSPIRE® (tezepelumab-ekko)	Inflammation	Severe Asthma	Monoclonal Antibody	3
	DESCRIPTION TEZSPIRE is a monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated for the reduction of oral corticosteroid use in adults with oral corticosteroid dependent asthma. **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc.			
	Inflammation	Chronic Rhinosinusitis with Nasal Polyps	Monoclonal Antibody	3
	DESCRIPTION TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc.			
	Inflammation	Eosinophilic Esophagitis	Monoclonal Antibody	3
	DESCRIPTION TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of eosinophilic esophagitis (EoE). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
	Inflammation	Chronic Obstructive Pulmonary Disease	Monoclonal Antibody	2
	DESCRIPTION TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic obstructive pulmonary disease (COPD). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc.			
	Inflammation	Chronic Spontaneous Urticaria	Monoclonal Antibody	2
	DESCRIPTION TEZSPIRE is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic spontaneous urticaria (CSU). **ADDITIONAL INFORMATION** TEZSPIRE is being developed in collaboration with AstraZeneca plc.			
UPLIZNA® **(inebilizumab-cdon)**	Rare Disease	IgG4-Related Disease	Monoclonal Antibody	3
	DESCRIPTION UPLIZNA is a humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody that binds to the B cell-specific surface antigen CD19. It is being investigated for the prevention of flares in patients with IgG4-related disease.			
	Rare Disease	Myasthenia Gravis	Monoclonal Antibody	3
	DESCRIPTION UPLIZNA is a humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody that binds to the B cell-specific surface antigen CD19. It is being investigated for improving outcomes in patients with myasthenia gravis.			
WEZLANA™ **(formerly ABP 654)** **(ustekinumab)**	Inflammation	Investigational Biosimilar	Monoclonal Antibody	3
	DESCRIPTION WEZLANA™ (formerly ABP 654) is an investigational biosimilar to STELARA (ustekinumab), which is a monoclonal antibody that inhibits IL-12 and IL-23. **ADDITIONAL INFORMATION** STELARA is a registered trademark of Johnson & Johnson.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
ABP 206 **(Investigational biosimilar to OPDIVO® (nivolumab))**	Hematology/Oncology	Investigational Biosimilar	Monoclonal Antibody	3
	DESCRIPTION ABP 206 is an investigational biosimilar to OPDIVO (nivolumab), which is a monoclonal antibody that binds to the receptor protein called programmed death protein 1 (PD-1). **ADDITIONAL INFORMATION** OPDIVO is a registered trademark of Bristol-Myers Squibb Company.			
ABP 234 **(Investigational biosimilar to KEYTUDA® (pembrolizumab))**	Hematology/Oncology	Investigational Biosimilar	Monoclonal Antibody	3
	DESCRIPTION ABP 234 is an investigational biosimilar to KEYTUDA (pembrolizumab), which is a monoclonal antibody that binds to the receptor protein called programmed death protein 1 (PD-1). **ADDITIONAL INFORMATION** KEYTUDA is a registered trademark of Merck & Co.			
ABP 938 **(Investigational biosimilar to EYLEA® (aflibercept))**	Inflammation	Investigational Biosimilar	Fusion Protein	3
	DESCRIPTION ABP 938 is an investigational biosimilar to EYLEA (aflibercept), which is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein. **ADDITIONAL INFORMATION** EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.			
ABP 959 **(Investigational biosimilar to SOLIRIS® (eculizumab))**	Hematology/Oncology	Investigational Biosimilar	Monoclonal Antibody	3
	DESCRIPTION ABP 959 is an investigational biosimilar to SOLIRIS (eculizumab), which is a monoclonal antibody that specifically binds to the complement protein C5. **ADDITIONAL INFORMATION** SOLIRIS is a registered trademark of Alexion Pharmaceuticals, Inc.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
DAXDILIMAB	Rare Disease	Dermatomyositis and Anti-Synthetase Inflammatory Myositis	Monoclonal Antibody	2
	DESCRIPTION Daxdilimab is a fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. It is being investigated for the treatment of dermatomyositis and anti-synthetase inflammatory myositis.			
	Rare Disease	Discoid Lupus Erythematosus	Monoclonal Antibody	2
	DESCRIPTION Daxdilimab is a fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. It is being investigated for the treatment of discoid lupus erythematosus.			
EFAVALEUKIN ALFA **(formerly AMG 592)**	Inflammation	Ulcerative Colitis	Fusion Protein	2
	DESCRIPTION Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of ulcerative colitis.			
FIPAXALPARANT	Rare Disease	Diffuse Cutaneous Systemic Sclerosis	Small Molecule	2
	DESCRIPTION Fipaxalparant is a molecule that blocks lysophosphatidic acid receptor 1 (LPAR1). It is being investigated for the treatment of diffuse cutaneous systemic sclerosis.			
	Rare Disease	Idiopathic Pulmonary Fibrosis	Small Molecule	2
	DESCRIPTION Fipaxalparant is a molecule that blocks lysophosphatidic acid receptor 1 (LPAR1). It is being investigated for the treatment of idiopathic pulmonary fibrosis.			
MARIDEBART CAFRAGLUTIDE **(MariTide, formerly AMG 133)**	Cardiometabolic	Obesity	Antibody-Peptide Conjugate	2
	DESCRIPTION Maridebart cafraglutide (MariTide, formerly AMG 133) is a gastric inhibitory polypeptide receptor (GIPR) antagonist and glucagon-like peptide 1 (GLP-1) receptor agonist. It is being investigated for the treatment of obesity.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
ORDESEKIMAB** (formerly AMG 714 / PRV-015)	Inflammation	Celiac Disease	Monoclonal Antibody	2
	DESCRIPTION Ordesekimab (formerly AMG 714/PRV-015) is a monoclonal antibody that inhibits the action of Interleukin-15 (IL-15). It is being investigated for the treatment of non-responsive celiac disease as an adjunct to a gluten free diet. **ADDITIONAL INFORMATION** Ordesekimab is being developed in collaboration with Provention Bio, a Sanofi company.			
AMG 329 (formerly HZN-1116)	Rare Disease	Sjögren's Disease	Monoclonal Antibody	2
	DESCRIPTION AMG 329 is a fully human monoclonal antibody that binds and neutralizes the function of the FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells. It is being investigated for the treatment of Sjögren's disease.			
XALURITAMIG (formerly AMG 509)	Hematology/Oncology	Prostate Cancer	XmAb® Antibody	1
	DESCRIPTION AMG 509 (STEAP1 XmAb antibody) is a bivalent T cell engager and is designed using XmAb 2+1 technology. It is being investigated for the treatment of prostate cancer. **ADDITIONAL INFORMATION** XmAb is a registered trademark of Xencor, Inc.			
AMG 104	Inflammation	Asthma	Monoclonal Antibody	1
	DESCRIPTION AMG 104 is a human anti-TSLP Fab. It is being investigated for the treatment of asthma. **ADDITIONAL INFORMATION** AMG 104 is being developed in collaboration with AstraZeneca plc.			
AMG 176	Hematology/Oncology	Hematology	Small Molecule	1
	DESCRIPTION AMG 176 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved

AMGEN® PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 193	Hematology/Oncology	Solid Tumors	Small Molecule	1
	DESCRIPTION AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. It is being investigated for the treatment of solid tumors. **ADDITIONAL CLINICAL STUDIES** AMG 193 is also in Phase 1 development for treatment of solid tumors in combination with other therapies.			
AMG 305	Hematology/Oncology	Colorectal Cancer	BiTE® Molecule	1
	DESCRIPTION AMG 305 is a dual-targeting bispecific T cell engager (BiTE) molecule against P-cadherin (CDH3), mesothelin (MSLN) and CD3. It is being investigated for the treatment of solid tumors.			
AMG 355	Hematology/Oncology	Solid Tumors	Monoclonal Antibody	1
	DESCRIPTION AMG 355 is an anti-CCR8 monoclonal antibody. It is being investigated for the treatment of advanced solid tumor malignancies.			
AMG 651	Hematology/Oncology	Colorectal Cancer	Bispecific T-Cell Engager	1
	DESCRIPTION AMG 651 (CX-904) is a T-cell engaging bispecific Probody® candidate against epidermal growth factor receptor (EGFR) and CD3. It is being investigated for the treatment of solid tumors. **ADDITIONAL INFORMATION** AMG 651 is being developed in collaboration with CytomX Therapeutics, Inc.			
AMG 794	Hematology/Oncology	Solid Tumors	BiTE® Molecule	1
	DESCRIPTION AMG 794 is a half-life extended (HLE) anti-claudin 6 (CLDN6) bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of solid tumors.			

*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

**Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.

‡ In addition to the above programs, AMJEVITA®/AMGEVITA®, MVASI®, KANJINTI®, and RIABNI® have been approved by the United States Food and Drug Administration (FDA) and the European Commission (EC). AVSOLA® has been approved by the FDA

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of May 2, 2024, and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.

AMGEN © 2024 Amgen Inc. All rights reserved